Ā | Patients without MLND Group A (Nā=ā261) | Patients with MLND Group B (Nā=ā29) | Value |
---|---|---|---|
Age | 60.6āĀ±ā12.1 | 61.4āĀ±ā11.0 | 0.751 |
Sex | Ā | Ā | 0.641 |
āMale | 200 (76.6%) | 24 (82.8%) | Ā |
āFemale | 61 (23.4%) | 5 (17.2%) | Ā |
BMI* | 23.6āĀ±ā3.5 | 23.0āĀ±ā3.5 | 0.492 |
ASA score** | Ā | Ā | 0.809 |
ā0 | 82 (31.4%) | 10 (34.4%) | Ā |
ā1 | 162 (62.0%) | 17 (58.6%) | Ā |
ā2 or more | 17 (6.5%) | 2 (6.8%) | Ā |
Siewert Type | Ā | Ā | 0.019 |
āType II | 103 (39.5%) | 18 (62.1%) | Ā |
āType III | 158 (60.5%) | 11 (37.9%) | Ā |
āTumor size | 4.4āĀ±ā2.5 | 5.7āĀ±ā2.9 | 0.025 |
Surgical procedure | Ā | Ā | <ā0.001 |
āTotal gastrectomy | 238 (91.2%) | 16 (55.2%) | Ā |
āProximal gastrectomy | 23 (8.8%) | 1 (3.4%) | Ā |
āEsophagectomy (Ivor Lewis) | 0 (0%) | 12 (41.4%) | Ā |
Splenectomy | Ā | Ā | 1.000 |
āYes | 17 (6.5%) | 1 (3.4%) | Ā |
āNo | 244 (93.5%) | 28 (96.6%) | Ā |
Histopathological type | Ā | Ā | 0.064 |
āDifferentiated | 103 (39.8%) | 16 (56.2%) | Ā |
āUndifferentiated | 142 (54.8%) | 13 (44.8%) | Ā |
āOthers | 14 (5.4%) | 0 (0%) | Ā |
Lauren classification | Ā | Ā | 0.006 |
āIntestinal | 144 (55.2%) | 12 (41.4%) | Ā |
āDiffuse | 79 (30.3%) | 8 (27.6%) | Ā |
āMixed | 24 (9.2%) | 2 (6.9%) | Ā |
āUnknown | 14 (5.4%) | 7 (24.1%) | Ā |
āProximal margin | 1.9āĀ±ā1.1 | 4.6āĀ±ā4.9 | <ā0.001 |
Extent of Abdominal | Ā | Ā | <ā0.001 |
āLN dissection | Ā | Ā | Ā |
āD1+ | 36 (13.8%) | 15 (51.7%) | Ā |
āD2 or more | 225 (86.2%) | 14 (48.3%) | Ā |
āHarvested LNs | 42.4āĀ±ā16.7 | 43.1āĀ±ā14.6 | 0.827 |
āMetastatic LNs | 3.0āĀ±ā6.4 | 5.8āĀ±ā6.7 | 0.043 |
T category | Ā | Ā | 0.035 |
āpT1 | 107 (41.0%) | 6 (20.7%) | Ā |
āpT2 | 45 (17.2%) | 5 (17.2%) | Ā |
āpT3 | 70 (26.8%) | 12 (41.4%) | Ā |
āpT4 | 39 (14.9%) | 6 (20.7%) | Ā |
pN category | Ā | Ā | 0.006 |
āpN0 | 158 (60.5%) | 6 (20.7%) | Ā |
āpN1 | 34 (13.0%) | 11 (37.9%) | Ā |
āpN2 | 26 (10.0%) | 5 (17.2%) | Ā |
āpN3 | 43 (16.5%) | 7 (24.1%) | Ā |
Cytology | Ā | Ā | 0.027 |
ānegative | 260 (99.6%) | 27 (93.1%) | Ā |
āPositive | 1 (0.4%) | 2 (6.9%) | Ā |
Stage*** | Ā | Ā | <ā0.001 |
āStage I | 147 (56.3%) | 6 (20.7%) | Ā |
āStage II | 54 (20.7%) | 12 (41.4%) | Ā |
āStage III | 57 (21.8%) | 8 (27.6%) | Ā |
āStage IV | 3 (1.1%) | 3 (10.3%) | Ā |
Adjuvant ChemoTx | 87 (33.3%) | 20 (68.9%) | <ā0.001 |